• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Nation's Top 40 High School Scientists to Compete for $1.8 Million in Awards at the Prestigious Regeneron Science Talent Search

    1/21/26 12:00:00 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $REGN alert in real time by email

    TARRYTOWN N.Y. and WASHINGTON, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Society for Science (the Society) and Regeneron today announced the top 40 finalists in the Regeneron Science Talent Search 2026, America's oldest and most prestigious science and math competition for high school seniors.

    Key Takeaways:

    • The Regeneron Science Talent Search 2026 finalists represent 35 schools across 15 states. They are competing for more than $1.8 million, with a top prize of $250,000 to further their scientific education.
    • 40 finalists were chosen from 300 top scholars, and more than 2,600 total entrants were selected based on the originality and creativity of their scientific research, as well as their achievement and leadership both inside and outside the classroom.
    • Finalists will participate in a week-long competition from March 5-11, 2026, engaging in a rigorous judging process and competing for awards that recognize their excellence and can be used toward their education.
    • They will also have an opportunity to interact with leading scientists and share research with the public on March 8, 2026.
    • The top 10 Regeneron Science Talent Search 2026 winners will be announced during an awards ceremony on March 10, streamed live from Washington D.C.
    • For a list of this year's finalists, see here: https://www.societyforscience.org/regeneron-sts/2026-finalists/.

    In its 85th year, the competition continues to spotlight exceptional young scientists whose technical excellence and leadership drive meaningful impact. Its alumni include 13 Nobel laureates, 23 MacArthur Fellows, eight Breakthrough Prize winners, and founders of influential science-driven companies such as Regeneron.

    "My own scientific journey can be traced back to my experience with the Science Talent Search, which profoundly shaped who I am today. Participating in and becoming a winner of STS gave me the confidence to dedicate my life to science and the pursuit of inventing medicines that improve people's lives," said George D. Yancopoulos, M.D., Ph.D., co-Founder, co-Chairman, President, and Chief Scientific Officer at Regeneron, and a 1976 STS Winner. "Today, Regeneron helps millions of people around the world facing serious diseases, which is a testament to what is possible when young scientific talent is nurtured. I see that same potential to transform our world in these finalists, and I eagerly await their future contributions to science and humanity."

    Finalist research projects cover 16 categories, from Computer Science to Environmental Science. Other finalists chose to focus on Behavioral Sciences. The top 4 categories among finalist projects this year are:

    1. Computer Science
    2. Computational Biology and Bioinformatics
    3. Mathematics
    4. Medicine and Health

    "We are immensely proud to celebrate this extraordinary class of Regeneron Science Talent Search finalists and their remarkable achievements," said Maya Ajmera, President and CEO of Society for Science and Executive Publisher of Science News. "As they build on a powerful 85-year legacy of scientific innovation, they are propelled by the strength and support of a dynamic scientific community."

    What's Next: Important Dates for 2026

    • Regeneron STS Finalists Week: March 5-11, 2026
    • Public Exhibition of Projects: March 8, 2026
    • Winners Announced at Awards Ceremony: March 10, 2026

    Resources:

    • Top 40 finalists
    • Top 300 scholars
    • Notable STS Alumni
    • STS 2025 Video Highlights

    What is the Regeneron Science Talent Search?

    The Regeneron Science Talent Search, a program of Society for Science since 1942, is the United States' oldest and most prestigious science and math competition for high school seniors. Each year, more than 2,000 student entrants submit original research in critically important scientific fields of study and are judged by leading experts in their fields. Unique among high school competitions in the U.S. and around the world, the Regeneron Science Talent Search focuses on identifying, inspiring and engaging the nation's most promising young scientists who are generating innovative solutions to solve significant global challenges through rigorous research and discoveries. It provides students with a national stage to present new ideas and challenge conventional ways of thinking.

    For over eight decades, the Science Talent Search has rewarded talented high school seniors who dedicate countless hours to original research projects and present their results in rigorous reports that resemble graduate school theses. Collectively, STS alumni have received millions of dollars in scholarships and gone on to be awarded Nobel Prizes, Fields Medals, MacArthur Fellowships and numerous other accolades.

    What is Regeneron's role?

    In 2017, Regeneron became only the third sponsor of the Science Talent Search, with a 10 year 100 million commitment to help reward and celebrate the best and brightest young minds and encourage them to pursue careers in STEM as a way to positively impact the world. Throughout our partnership, Regeneron nearly doubled the overall award distribution to $3.1 million annually, increasing the top award to $250,000 and doubling the awards for the top 300 scholars to $2,000 and their schools to $2,000 for each enrolled scholar to inspire more young people to engage in science.

    Learn more at https://www.societyforscience.org/regeneron-sts/.

    What is Society for Science?

    Society for Science is a champion for science, dedicated to promoting the understanding and appreciation of science and the vital role it plays in human advancement. Established in 1921, Society for Science is best known for its award-winning journalism through Science News and Science News Explores, its world-class science research competitions for students, including the Regeneron Science Talent Search, the Regeneron International Science and Engineering Fair and the Thermo Fisher Scientific Junior Innovators Challenge, and its STEM Outreach programming that seeks to ensure that all students have an opportunity to pursue a career in STEM. A 501(c)(3) membership organization, Society for Science is committed to inform, educate and inspire. Learn more at www.societyforscience.org and follow us on Facebook, Twitter, Instagram, and LinkedIn.

    What is Regeneron?

    Regeneron (NASDAQ:REGN) is a leading biotechnology company that invents, develops, and commercializes potentially life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, hematologic conditions, infectious diseases, and rare diseases.

    Regeneron believes that operating as a good corporate citizen is crucial to delivering on our mission. We approach corporate responsibility with three goals in mind: to improve the lives of people with serious diseases, to foster a culture of integrity and excellence, and to build sustainable communities. Our most significant philanthropic investments are in science education, a commitment we call STEM-Fueled™ – our collection of programs and partnerships, including the Regeneron Science Talent Search (STS) and the Regeneron International Science and Engineering Fair (ISEF), that fuel future scientific innovators to pursue bold ideas and advance world-changing solutions. Throughout the year, Regeneron empowers and supports employees to give back through our volunteering, pro bono, and matching gift programs. We are proud to be recognized on the Dow Jones Sustainability World Index and the Civic 50 list of the most "community-minded" companies in the United States.

    For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.

    Media Contacts

    Gayle Kansagor, Society for Science

    703-489-1131, [email protected]

    Tina Parisi Tuttle, Regeneron

    914-847-3511, [email protected] 



    Primary Logo

    Get the next $REGN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $REGN

    DatePrice TargetRatingAnalyst
    1/7/2026$860.00Underperform → Buy
    BofA Securities
    12/3/2025$767.00Overweight → Equal-Weight
    Morgan Stanley
    11/24/2025$798.00Buy
    Truist
    11/24/2025$255.00Buy
    HSBC Securities
    11/13/2025$650.00Sector Perform
    Scotiabank
    8/14/2025$890.00Buy
    Rothschild & Co Redburn
    6/30/2025Buy → Hold
    Argus
    5/30/2025$662.00Outperform → Sector Perform
    RBC Capital Mkts
    More analyst ratings

    $REGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bassler Bonnie L exercised 1,500 shares at a strike of $374.12 and sold $1,200,000 worth of shares (1,500 units at $800.00) (SEC Form 4)

    4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)

    1/8/26 4:03:19 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Zoghbi Huda Y was granted 155 shares, increasing direct ownership by 10% to 1,703 units (SEC Form 4)

    4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)

    1/6/26 4:21:24 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Thompson Craig B. was granted 155 shares, increasing direct ownership by 25% to 775 units (SEC Form 4)

    4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)

    1/6/26 4:18:21 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $REGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nation's Top 40 High School Scientists to Compete for $1.8 Million in Awards at the Prestigious Regeneron Science Talent Search

    TARRYTOWN N.Y. and WASHINGTON, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Society for Science (the Society) and Regeneron today announced the top 40 finalists in the Regeneron Science Talent Search 2026, America's oldest and most prestigious science and math competition for high school seniors. Key Takeaways: The Regeneron Science Talent Search 2026 finalists represent 35 schools across 15 states. They are competing for more than $1.8 million, with a top prize of $250,000 to further their scientific education.40 finalists were chosen from 300 top scholars, and more than 2,600 total entrants were selected based on the originality and creativity of their scientific research, as well as their ac

    1/21/26 12:00:00 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Regeneron to Report Fourth Quarter and Full Year 2025 Financial and Operating Results and Host Conference Call and Webcast on January 30, 2026

    TARRYTOWN, N.Y., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2025 financial and operating results on Friday, January 30, 2026, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the 'Investors and Media' page of Regeneron's website at https://investor.regeneron.com. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation

    1/2/26 4:05:00 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Press Release: Sanofi and Regeneron's Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma

    Sanofi and Regeneron's Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma Approval based on global phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function compared to placebo (by 4.68% to 5.32%)    Dupixent is the first and only biologic medicine to demonstrate improved lung function in this young patient group in a randomized phase 3 study, and inhibits IL-4 and IL-13, two key and central drivers of type 2 inflammation Paris and Tarrytown, NY, December 23, 2025. The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent (dupil

    12/23/25 1:00:00 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $REGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Regeneron Pharma upgraded by BofA Securities with a new price target

    BofA Securities upgraded Regeneron Pharma from Underperform to Buy and set a new price target of $860.00

    1/7/26 8:45:07 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Regeneron Pharma downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Regeneron Pharma from Overweight to Equal-Weight and set a new price target of $767.00

    12/3/25 8:30:10 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Truist resumed coverage on Regeneron Pharma with a new price target

    Truist resumed coverage of Regeneron Pharma with a rating of Buy and set a new price target of $798.00

    11/24/25 9:17:24 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $REGN
    SEC Filings

    View All

    Regeneron Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)

    1/12/26 6:48:25 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 13F-HR filed by Regeneron Pharmaceuticals Inc.

    13F-HR - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)

    11/7/25 4:55:01 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Regeneron Pharmaceuticals Inc.

    10-Q - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)

    10/28/25 6:56:36 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $REGN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    May 20, 2022 - FDA Approves First Treatment for Eosinophilic Esophagitis, a Chronic Immune Disorder

    For Immediate Release: May 20, 2022 Today, the U.S. Food and Drug Administration approved Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in adults and pediatric patients 12 years and older weighing at least 40 kilograms (which is about 88 pounds). Today’s action marks the first FDA approval of a treatment for EoE. “As researchers and clinicians have gained knowledge about eosinophilic esophagitis

    5/20/22 3:11:09 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $REGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Regeneron Pharmaceuticals Inc. (Amendment)

    SC 13G/A - REGENERON PHARMACEUTICALS, INC. (0000872589) (Subject)

    2/13/24 5:12:22 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Regeneron Pharmaceuticals Inc. (Amendment)

    SC 13G/A - REGENERON PHARMACEUTICALS, INC. (0000872589) (Subject)

    2/9/24 6:19:03 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Regeneron Pharmaceuticals Inc. (Amendment)

    SC 13G/A - REGENERON PHARMACEUTICALS, INC. (0000872589) (Subject)

    2/9/24 9:49:31 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $REGN
    Financials

    Live finance-specific insights

    View All

    Regeneron to Report Fourth Quarter and Full Year 2025 Financial and Operating Results and Host Conference Call and Webcast on January 30, 2026

    TARRYTOWN, N.Y., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2025 financial and operating results on Friday, January 30, 2026, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the 'Investors and Media' page of Regeneron's website at https://investor.regeneron.com. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation

    1/2/26 4:05:00 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lynozyfic™ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment

    All three dose groups (50 mg, 100 mg and 200 mg) showed impressive monotherapy efficacy, with VGPR+ (very good partial response or better) of ≥70% despite limited follow-up; evidence shows that these responses are expected to deepen over time Across all dose groups, 95% (19 of 20 patients) of all evaluable VGPR+ patients achieved minimal residual disease negative status Data featured in an ASH oral presentation; LINKER-MM4 is the first clinical trial to evaluate a BCMAxCD3 bispecific monotherapy in NDMM and is part of a broad clinical development program evaluating Lynozyfic-based regimens in earlier lines of treatment Regeneron to host virtual ‘Regeneron Roundtable' investor event to dis

    12/7/25 4:30:00 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Regeneron Highlights Progress at American Society of Hematology (ASH), with Updated Data in Multiple Myeloma, Lymphoma and Paroxysmal Nocturnal Hemoglobinuria Programs

    Oral presentation of Lynozyfic™ (linvoseltamab-gcpt) data in newly diagnosed multiple myeloma from LINKER-MM4, the first trial to evaluate a BCMAxCD3 bispecific antibody as a monotherapy in this setting Additional oral presentation spotlights data for odronextamab in combination with chemotherapy, without rituximab, as a frontline treatment for diffuse large B-cell lymphoma Other presentations span a broad range of hematologic conditions, including paroxysmal nocturnal hemoglobinuria and severe aplastic anemia Regeneron to host virtual ‘Regeneron Roundtable' investor event to discuss its multiple myeloma development program on Wednesday, December 10 at 8:30 a.m. ET TARRYTOWN, N.Y., Nov.

    11/13/25 7:00:00 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $REGN
    Leadership Updates

    Live Leadership Updates

    View All

    Regeneron Announces First-of-its-Kind Donation Matching Program with Independent Charitable Patient Assistance Organization

    TARRYTOWN, N.Y., June 24, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced the launch of a pioneering matching program for donations to Good Days, an independent national non-profit charitable organization, to support Good Days' Retinal Vascular and Neovascular Disease Fund. Through this initiative, Regeneron has committed to matching donations up to a total of $200 million at a one-to-one rate for the remainder of the 2025 calendar year, enabling more patients to affordably access essential medicines that help protect their vision. "We are proud to support Good Days with this unprecedented philanthropic effort," said Leonard Schleifer, M.D., Ph.D.,

    6/24/25 7:30:00 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical Programs

    TARRYTOWN, N.Y., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced the formation of Regeneron Cell Medicines based on an agreement with 2seventy bio, Inc. to acquire full development and commercialization rights to its pipeline of investigational novel immune cell therapies, along with its discovery and clinical manufacturing capabilities. 2seventy bio employees who support the acquired programs will join Regeneron Cell Medicines, a newly formed research & development (R&D) unit to advance cell therapies and combination approaches in oncology and immunology. "Regeneron and 2seventy share a relentless commitment to push the boundaries of scie

    1/30/24 7:00:41 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Together for CHANGE Genomics and Equity Initiative Launched by a Coalition of Meharry Medical College, Regeneron Genetics Center, AstraZeneca, Novo Nordisk, and Roche to Improve Health Outcomes for People of African Ancestry

    NIH data show that globally less than 2% of genetic information being studied today originates from people of African ancestry1 The newly established Diaspora Human Genomics Institute (DHGI) will manage the Together for CHANGE initiative, which aims to increase available genomic data for people of African ancestry and enhance representation in STEM careers NASHVILLE, Tenn. and TARRYTOWN, N.Y. and WILMINGTON, Del. and BAGSVAERD, Denmark and BASEL, Switzerland, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Meharry Medical College, along with partners Regeneron Genetics Center® (RGC™), AstraZeneca, Novo Nordisk, and Roche, today announced the launch of the Together for CHANGE™ ("Changing Healthcare for

    10/18/23 9:00:00 AM ET
    $AZN
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care